We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Tool Exposes Hidden Cancer DNA Changes Driving Treatment Resistance

By LabMedica International staff writers
Posted on 07 Aug 2025

Some of the most damaging genetic changes in cancer are also the most difficult to detect. More...

Structural alterations buried deep within a tumor's DNA can drive aggressive growth and evade traditional testing methods, especially when tumor samples are small or degraded. These hidden genomic changes can interfere with accurate diagnosis and hinder the development of effective treatment strategies. Now, researchers have developed a new tool that exposes previously invisible layers of genomic instability and provides insights into how tumors might behave and respond to treatment.

The new tool, named BACDAC, has been developed by researchers at Mayo Clinic (Rochester, MN, USA) to identify signs of genomic instability using whole-genome DNA sequencing, even in low-purity or low-coverage tumor samples. At the heart of BACDAC's functionality is the concept of ploidy, or the number of complete chromosome sets in a cell. While healthy cells contain two sets of chromosomes, cancer cells often exhibit abnormal changes such as whole-genome doubling, a phenomenon that disrupts chromosomal balance and enables uncontrolled tumor growth.

BACDAC also features a unique visual interface known as the Constellation Plot, which provides a clear and intuitive summary of a tumor’s genomic landscape, helping pathologists and researchers determine whether a tumor’s chromosomes are stable or disrupted. The researchers validated BACDAC by applying it to over 650 tumors across 12 different cancer types. The findings, published in the journal Genome Biology, show that the tool successfully detected indicators of whole-genome doubling, a structural abnormality frequently associated with aggressive tumors and resistance to therapy.

The team now plans to further validate BACDAC and develop it into a clinically deployable diagnostic platform. By offering a clearer view of complex genomic alterations, this tool could inform more personalized cancer treatments and improve outcomes for patients facing hard-to-treat cancers.

"This tool lets us see a layer of the genome that's been invisible until now. We've spent decades studying the biology of genomic instability. This is the first time we've been able to translate that knowledge into a tool that works at scale, " said George Vasmatzis, Ph.D., lead author of the study.

Related Links:
Mayo Clinic


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: An innovative deep learning model can accurately predict MSI tumor and immune checkpoint inhibitor responsiveness (Photo courtesy of Jae-Ho Cheong/Yonsei University College of Medicine)

AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness

One in three people is expected to develop cancer in their lifetime, and a key factor in patient prognosis is the tumor’s microsatellite status—whether it is stable or shows microsatellite instability-high (MSI-H).... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.